Coming soon. First inventory is in final QC.Coming soon
Compliance
You must be 21 or older. Agree to the following terms before accessing product information and pricing.
Research Use Policy Summary
For laboratory research use only. Not for human or veterinary consumption, diagnostic use, therapeutic use, or clinical use.

Growth Hormone Research
Accept the research disclaimer to view pricing and purchase options.
Product Usage Notice · This product is intended strictly for research and laboratory use only. It is designated for in vitro testing and experimental purposes. Any use involving human or animal consumption is prohibited by law. All information provided on this website is for educational purposes only. This product must only be handled by licensed, qualified professionals. It is not intended for use as a drug, food, or cosmetic, and must not be misused, mislabeled, or misrepresented as such. Read full Research Use Policy →
Technical specifications
CJC-1295 without DAC (also known as Modified GRF 1-29) is a truncated GHRH analog with four amino acid substitutions for improved stability, used in research on pulsatile growth hormone release.
Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295 in endocrine receptor pharmacology literature Journal of Endocrinology & Metabolism Published pharmacology literature examining CJC-1295 GH axis signaling mechanisms. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.
View StudyPulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295 Journal of Endocrinology & Metabolism Published pharmacology literature examining GH pulsatility preservation mechanisms. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.
View StudyActivation of the GH/IGF-1 Axis by CJC-1295 in endocrine receptor pharmacology literature Growth Hormone & IGF Research Proteomic analysis describing GH/IGF-1 axis pathway markers following CJC-1295 exposure. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.
View StudyCJC-1295, a Long-Acting GHRH Analog, and GH/IGF-1 Axis Signaling in endocrine receptor pharmacology literature Journal of Endocrinology & Metabolism Published pharmacology literature examining long-acting GHRH analog receptor signaling. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.
View StudyCombination of GHRH Analog with GHRP Achieves Synergistic GH Release Journal of Endocrinology & Metabolism Published study examining synergistic GH axis receptor engagement when combining GHRH and GHRP mechanisms. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.
View StudyGrowth Hormone-Releasing Hormone in published pharmacology Practice: Focus on Long-Acting Analogs Endocrinology and Metabolism Clinics of North America Published review examining CJC-1295 pharmacokinetics including albumin-binding half-life extension and IGF-I axis modulation. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.
View StudyThis compound is supplied strictly for in-vitro and preclinical research use only. Primary applications include the areas below.
Tool compound for investigating GHRH receptor activation and pulsatile GH secretion kinetics in cell-based and preclinical models.
Evaluates GH/IGF-1 axis signaling and downstream pathway pharmacology in preclinical metabolic research models.
Lot records organize identity, purity, storage context, and supporting COA documentation for laboratory intake review.
Lot documentation reports 99%+ purity and identity verification by the listed analytical method.
Explore